Skip to content

Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02221830
Acronym
PHP3
Enrollment
66
Registered
2014-08-20
Start date
2015-02-28
Completion date
2019-07-17
Last updated
2021-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Brief summary

Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

Detailed description

The overall goal of this study is to evaluate the efficacy of postpartum 24 hour oxytocin infusion as a prevention-oriented strategy to reduce blood loss in patients with pre-eclampsia (PE) in a blinded, placebo controlled, randomized controlled trial.

Interventions

DRUGOxytocin

Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)

DRUGPlacebo

This intervention utilizes a Placebo Camparator

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
13 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age; 2. diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of \> 300mg per 24 hour period or \> 1+ on dipstick). 3. patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis)

Exclusion criteria

1. abnormal placentation (previa, accreta, etc) 2. antenatal hemorrhage 3. contraindication to oxytocin

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Postpartum hematocrit24 hours postpartumPostpartum hematocrit (collected 24 hours after delivery unless patient receives blood transfusion, then pre-transfusion hematocrit will be used)

Secondary

MeasureTime frameDescription
Primary postpartum hemorrhageBefore discharge from hospitalConsidered to be \>500ml with vaginal deliveries,or, \>1000ml with cesarean sections.
Estimated blood loss at deliveryBefore discharge from hospitalEstimated blood loss at delivery
Postpartum blood loss24 hours postpartumPostpartum blood loss: 24hrs postpartum, as measured by pad counts and weights.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026